23.05.2022 01:54

Vibrant's Novel Drug-Free Treatment Demonstrates Positive Efficacy and Safety Results in Adults with Chronic Idiopathic Constipation in Pivotal Phase 3 Study

Folgen
Werbung
  • The Phase 3 data met all primary endpoints for complete spontaneous bowel movements (CSBMs) per week and showed significant improvement in secondary outcomes versus placebo
  • Data validates Vibrant as a safe and well-tolerated option to address unmet treatment needs in chronic idiopathic constipation (CIC)
  • Company submitted Phase 3 data to the U.S. Food and Drug Administration for clearance

NANTUCKET, Mass., May 22, 2022 /PRNewswire/ -- Vibrant Gastro, a medical technology company that developed a proprietary, drug-free treatment for chronic idiopathic constipation (CIC) in adults, today presented data results from its positive Phase 3 study at the 2022 Digestive Disease Week Conference. The data shows that Vibrant significantly improved complete bowel movement frequency, constipation symptoms, and quality of life in adults with CIC while providing a safe and well-tolerated safety profile.

Satish Rao, M.D., Ph.D., professor of medicine at Augusta University, and one of the primary study investigators

"This research demonstrates that Vibrant's unique drug-free mechanism of action significantly improves patients' overall constipation symptoms and quality of life," said Lior Ben-Tsur, CEO, Vibrant. "Vibrant offers healthcare providers a new tool to expand chronic constipation treatment options and may provide a cost-effective solution for chronic constipation for health systems and insurance companies."

The Phase 3 trial evaluated the safety and efficacy of Vibrant System in 312 CIC patients at over 90 clinical centers across the U.S., including Harvard Medical School, Augusta University, Georgia Health Sciences University, University of Michigan, and Houston Methodist Hospital.

Highlights from Phase 3 Data

  • The trial met all primary endpoints for complete spontaneous bowel movements (CSBMs) per week and showed significant improvement in secondary outcomes versus placebo.
    • 39.26% of patients receiving Vibrant System had one or more additional CSBMs per week, compared to baseline vs. 22.15% in the placebo group (p<0.0001).
    • 22.7% of patients receiving Vibrant System had two or more additional CSBMs per week, compared to baseline vs. 11.41% in the placebo group (p<0.0006).
    • Data showed significant improvement in secondary outcomes vs. placebo for stool consistency (p<0.001), quality of life (p=0.0020), and straining (p<0.0139).
  • No severe adverse events or treatment-related diarrhea or nausea were recorded.

"The goal of Vibrant is to address a significant unmet treatment problem in chronic constipation, which has made life very challenging for those who suffer from it. We believe Vibrant presents a meaningful step toward achieving that goal," said Satish Rao, M.D., Ph.D., professor of medicine, and one of the primary study investigators.

Vibrant's drug-free mechanism of action is based on the scientific understanding that the circadian rhythm, otherwise known as "the biological clock," plays an important role in our biological digestive process. When the biological clock is out of synch, people are more likely to experience constipation. Vibrant's technology resynchronizes the biological clock through mechanical stimulation of the colon, likely leveraging the Gut-Brain connection, resulting in improved bowel movements, constipation symptoms relief, and better quality of life.

"Additionally, as we innovate in the gastroenterology space, we have the opportunity to help millions of CIC patients gain access to novel drug-free treatments that offer predictable, affordable, and effective choices to manage their frequent and bothersome symptoms," shared Catherine Collis, Vibrant's CCO.

Based on the Phase 3 results, Vibrant has submitted its system to the U.S. Food and Drug Administration for clearance.

About Vibrant

Vibrant is the pioneer of a unique mechanism of action for the treatment of chronic idiopathic constipation (CIC), based on the scientific understanding that when the biological clock is out of synch, people are more likely to experience constipation.

The orally administered drug-free disposable capsule is directed by a pod, which activates and sends the operating instructions to the capsule. The capsule, once ingested, resynchronizes the biological clock through mechanical stimulation of the colon, resulting in improved bowel movements, constipation symptoms relief, and better quality of life.

The treatment's companion app, assisting patients to self-track their treatment progress, helps obtain a better state of health.     

The Vibrant capsule is an investigational device limited to investigational use in the United States. It is currently under FDA review and is not available for sale.

To learn more about Vibrant, visit www.vibrantgastro.com.

Lior Ben-Tsur, CEO, Vibrant

(PRNewsfoto/Vibrant)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vibrants-novel-drug-free-treatment-demonstrates-positive-efficacy-and-safety-results-in-adults-with-chronic-idiopathic-constipation-in-pivotal-phase-3-study-301552332.html

SOURCE Vibrant

Jetzt noch kostenlos anmelden!

Inflation, Leitzinserhöhung und Bärenmärkte - aber wie sieht es eigentlich am Immobilienmarkt aus? Wenn auch Sie sich den Traum einer eigenen Immobilie erfüllen möchten, erfahren Sie im Online-Seminar am Montag um 18 Uhr wie Sie Schritt für Schritt das passende Objekt finden und welche Finanzierungsmöglichkeiten es gibt!

Werbung
Werbung
Werbung
Neue Funktionen als Erstes nutzen
Sie nutzen finanzen.net regelmäßig? Dann nutzen Sie jetzt neue Funktionen als Erstes!
Hier informieren!
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

Ukraine-Krieg im Ticker: DAX schließt Freitagshandel über 13.100 Punkten -- US-Börsen legen markant zu -- Zalando kassiert Jahresprognose -- GAZPROM, TUI, Porsche-IPO, Amazon, Deutsche Bank im Fokus

IMMOFINANZ will Objekte in Milliardenwert verkaufen. Streik des Kabinen-Personals führt zu Flug-Ausfällen bei Ryanair. Henkel macht laut CEO Knobel Fortschritte beim Rückzug aus Russland. RWE plant Wasserstoff-Produktionsanlage in Rostock. Stellantis steigt bei Lithium-Unternehmen Vulcan Energy ein. Stifel startet Vonovia mit "Hold". Zurich trennt sich von deutschen Lebensversicherungs-Altbeständen.

Umfrage

Sollte das 9-Euro-Ticket über den August hinaus verlängert werden?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln